Clinical Trials Logo

Primary Myelofibrosis clinical trials

View clinical trials related to Primary Myelofibrosis.

Filter by:

NCT ID: NCT01236638 Completed - Clinical trials for Primary Myelofibrosis

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated.

NCT ID: NCT01233921 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Start date: September 2010
Phase: N/A
Study type: Interventional

RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant. PURPOSE: This randomized clinical trial studies palifermin in preventing chronic graft-versus-host disease in patients who have undergone donor stem cell transplant for hematologic cancer

NCT ID: NCT01224496 Completed - Clinical trials for Myelodysplastic Syndrome (MDS)

Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to study the efficacy of Traditional Chinese Medicine (TCM) on anaemic and cytopenic haematological disorders including myelodysplastic syndrome (MDS), aplastic anaemia (AA), myelofibrosis (MF) and thalassemia intermedia who do not have or did not respond to available treatment options.

NCT ID: NCT01200498 Completed - Clinical trials for Myeloproliferative Disorders

Study of SB939 in Subjects With Myelofibrosis

Start date: November 2010
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if SB939 can help to control myelofibrosis. The safety of this drug will also be studied.

NCT ID: NCT01199562 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Start date: December 2010
Phase:
Study type: Observational

RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.

NCT ID: NCT01178281 Completed - Clinical trials for Primary Myelofibrosis

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

RESUME
Start date: September 8, 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global study) and in reversing anemia in Chinese with MPN-associated myelofibrosis and severe anemia not receiving RBC-transfusions (China extension study only)

NCT ID: NCT01149915 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the maximum tolerated dose, dose limiting toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase chronic myelogenous leukemia (CML), high risk myelodysplastic syndromes, advanced myelofibrosis or relapsed/refractory chronic lymphocytic leukemia (CLL).

NCT ID: NCT01149681 Completed - Myelofibrosis Clinical Trials

Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This is an open-label, Phase II Clinical Trial of Aplidin® (plitidepsin) in Patients with Primary Myelofibrosis and post polycythemia vera/essential thrombocythemia (Post-PV/ET) Myelofibrosis.

NCT ID: NCT01134120 Completed - Clinical trials for Primary Myelofibrosis

A Study in Myeloproliferative Disorders

Start date: April 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

NCT ID: NCT01093586 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: September 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor umbilical cord blood stem cell transplant works in treating patients with hematologic malignancies.